Abstract
The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) altered the logistics of ongoing randomized controlled trials (RCTs). The need to reduce in-person research and clinical activities, however, presented an additional level of complexity in order to continue conducting RCTs that focused on the development of medications for Alcohol Use Disorder (AUD). The visits required a systematic objective evaluation from the physician and mental health professional and clinical staff, as many of the safety and efficacy assessments are self-reported. The following commentary addresses the successes and limitations our RCTs encountered during the coronavirus (COVID-19) pandemic.
All Keywords
【초록키워드】 COVID-19, Randomized controlled trial, SARS-CoV-2, Efficacy, coronavirus, pandemic, mental health, medications, alcohol, RCT, Research, assessment, medication, RCTs, acute respiratory syndrome, mental health professional, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, complexity, activities, limitation, logistics, disorder, required, reduce, 【제목키워드】 COVID-19 pandemic, Controlled trial,
【초록키워드】 COVID-19, Randomized controlled trial, SARS-CoV-2, Efficacy, coronavirus, pandemic, mental health, medications, alcohol, RCT, Research, assessment, medication, RCTs, acute respiratory syndrome, mental health professional, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, complexity, activities, limitation, logistics, disorder, required, reduce, 【제목키워드】 COVID-19 pandemic, Controlled trial,
{{{ 추상적인 }}}
새로운 중증 급성 호흡기 증후군 코로나바이러스 2(SARS-CoV-2)는 진행 중인 무작위 대조 시험(RCT)의 물류를 변경했습니다. 그러나 대면 연구 및 임상 활동을 줄여야 하는 필요성은 알코올 사용 장애(AUD)에 대한 약물 개발에 초점을 맞춘 RCT를 계속 수행하기 위해 추가적인 수준의 복잡성을 제시했습니다. 많은 안전성 및 효능 평가가 자가 보고되기 때문에 방문에는 의사, 정신 건강 전문가 및 임상 직원의 체계적이고 객관적인 평가가 필요했습니다. 다음 논평은 코로나바이러스(COVID-19) 팬데믹 기간 동안 RCT가 직면한 성공과 한계에 대해 설명합니다.